Kinase News and Research

RSS

AstraZeneca to take over Probiodrug's CDK9 inhibitor program

Probiodrug AG announced today the transfer of its experimental cyclin-dependent kinase 9 inhibitor program to AstraZeneca. The transaction includes the sale to AstraZeneca of a lead molecule and back-up compounds with the associated intellectual property. CDK9, which has been implicated in the transcriptional regulation of genes involved in proliferation and inflammation, is a promising target for the treatment of both cancer and inflammatory diseases.

3 Jan 2014

University of Utah discovers cellular mechanism that stops metastasis of breast cancer

Researchers from Huntsman Cancer Institute (HCI) at the University of Utah discovered a cellular mechanism that drives the spread of breast cancer to other parts of the body (metastasis), as well as a therapy which blocks that mechanism. The research results were published online in the journal Cell Reports on January 2.

3 Jan 2014

Rho-associated protein kinase regulates hippocampal neurite growth, microtubule formation

Rho-associated protein kinase is an essential regulator of cytoskeletal dynamics during the process of neurite extension. However, whether Rho kinase regulates microtubule remodeling or the distribution of adhesive proteins to mediate neurite outgrowth remains unclear.

28 Dec 2013

Researchers complete genomic analysis of cervical cancer in two patient populations

Researchers from the Boston area, Mexico, and Norway have completed a comprehensive genomic analysis of cervical cancer in two patient populations. The study identified recurrent genetic mutations not previously found in cervical cancer, including at least one for which targeted treatments have been approved for other forms of cancer.

25 Dec 2013

Experimental drug inhibits BTK molecule in patients with chronic lymphocytic leukemia

A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) helps confirm that a molecule targeted by the experimental drug ibrutinib is critical for the development of chronic lymphocytic leukemia, the most common form of adult leukemia.

20 Dec 2013

BeiGene doses first patient in Phase 1 study of BGB-283

BeiGene (Beijing), Co., Ltd., today announced dose administration for the first patient in a Phase 1 study of BGB-283 in patients with B-RAF or K-RAS mutations. BGB-283 is an investigational, oral, selective, potent second generation inhibitor of B-RAF, making it a targeted therapeutic candidate to potentially treat and bring benefit to patients with cancers that harbor BRAF mutations and/or aberrations in the RAS-MAPK (mitogen-activated protein kinase) pathway.

20 Dec 2013

Merck and CNIO sign agreement to collaborate in area of cancer drug development

The Spanish National Cancer Research Centre (CNIO) and the German chemical and pharmaceutical company Merck today signed an agreement in Madrid to collaborate in the area of cancer drug development.

19 Dec 2013

Merck signs license agreement with CNIO for cancer drug development

Merck Serono, the biopharmaceutical division of Merck, today announced that a license agreement has been signed with the Spanish National Cancer Research Centre in Madrid in the area of cancer drug development. The global agreement will build upon CNIO research discoveries to encourage the development and commercialization of new compounds in the field of oncology.

18 Dec 2013

Merck initiates clinical trial to evaluate MK-3475 and pazopanib in advanced renal cell carcinoma

Merck, known as MSD outside the United States and Canada, today announced the initiation of a clinical trial to evaluate the combination of the company's investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline's orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma.

18 Dec 2013

Genetically targeted drugs used for lung cancer may also have applications in colorectal cancer patients

A University of Colorado Cancer Center study published online ahead of print in the journal Molecular Cancer Research shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. These results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of colorectal cancer patients.

17 Dec 2013

UCLA scientists receive $21M grant to conduct groundbreaking clinical trials on stem cell science

Scientists from UCLA are now bringing their groundbreaking stem cell science directly to patients in two exciting new clinical trials scheduled to begin in early 2014, thanks to funding from California's stem cell agency.

17 Dec 2013

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

BerGenBio AS, an oncology biopharmaceutical company, announces that preclinical data demonstrating that BGB324 has potential application as a novel treatment for Chronic Myeloid Leukemia, was presented in a poster at the Annual Meeting of the American Society of Hematology, which took place on December 7-10, 2013.

17 Dec 2013

Researchers identify new method to predict outcomes in heart failure patients

Researchers at the George Washington University School of Medicine and Health Sciences (SMHS) and Johns Hopkins University School of Medicine have identified a new method to determine whether a patient's heart will fail, which in the future may help physicians better treat patients and tailor therapeutic interventions.

16 Dec 2013

Study could lead towards a personalised medicine for chemoresistant lymphomata

To date, tests have only been carried out on cells, but a piece of research conducted by the Department of Genetics at the UPV/EHU's Faculty of Medicine in collaboration with MD Anderson and the CNIO is opening up the door for the treatment of lymphoma types that have a lower survival rate. The study of the molecular characteristics of the tumours would enable molecules that are altered in a specific way to be identified and turned into new therapeutic targets that would improve the prognosis of patients with chemoresistant lymphomata.

16 Dec 2013

Research reveals that deletion of Epac1 gene protects from fatal rickettsiosis

Researchers at the University of Texas Medical Branch at Galveston have discovered a way to block a disease pathway that could be a breakthrough in defeating some of the world's most devastating human infections.

14 Dec 2013

Researchers discover completely new targets for treatment of blood cancers

A particularly aggressive form of leukemia is the acute lymphoblastic leukemia (ALL). It is especially common among children and very difficult to treat. Researchers from the University of Veterinary Medicine, Vienna have now discovered completely new targets for the treatment of blood cancers.

13 Dec 2013

Scientists bring stem cell science directly to patients

Scientists from UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research are bringing stem cell science funded by the California Institute of Regenerative Medicine (CIRM), the state stem cell agency, directly to patients in two exciting new clinical trials scheduled to begin in early 2014.

13 Dec 2013

New strategy for fighting infection targets patient's cells rather than invading pathogens

As more reports appear of a grim "post-antibiotic era" ushered in by the rise of drug-resistant bacteria, a new strategy for fighting infection is emerging that targets a patient's cells rather than those of the invading pathogens.

12 Dec 2013

New test to help physicians identify patients with most lethal forms of triple-negative breast cancer

A new test has the potential to help physicians identify patients with the most lethal forms of triple-negative breast cancer, a disease which requires aggressive and innovative treatment.

12 Dec 2013

Researchers find decreased energy metabolism in heart cells as significant independent risk factor

Johns Hopkins researchers have identified a new way to predict which heart failure patients are likely to see their condition get worse and which ones have a better prognosis. Their study is one of the first to show that energy metabolism within the heart, measured using a noninvasive magnetic resonance imaging test, is a significant predictor of clinical outcomes, independent of a patient's symptoms or the strength of the heart's ability to pump blood, known as the ejection fraction.

11 Dec 2013

Kinase News and Research

AstraZeneca to take over Probiodrug's CDK9 inhibitor program

University of Utah discovers cellular mechanism that stops metastasis of breast cancer

Rho-associated protein kinase regulates hippocampal neurite growth, microtubule formation

Researchers complete genomic analysis of cervical cancer in two patient populations

Experimental drug inhibits BTK molecule in patients with chronic lymphocytic leukemia

BeiGene doses first patient in Phase 1 study of BGB-283

Merck and CNIO sign agreement to collaborate in area of cancer drug development

Merck signs license agreement with CNIO for cancer drug development

Merck initiates clinical trial to evaluate MK-3475 and pazopanib in advanced renal cell carcinoma

Genetically targeted drugs used for lung cancer may also have applications in colorectal cancer patients

UCLA scientists receive $21M grant to conduct groundbreaking clinical trials on stem cell science

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

Researchers identify new method to predict outcomes in heart failure patients

Study could lead towards a personalised medicine for chemoresistant lymphomata

Research reveals that deletion of Epac1 gene protects from fatal rickettsiosis

Researchers discover completely new targets for treatment of blood cancers

Scientists bring stem cell science directly to patients

New strategy for fighting infection targets patient's cells rather than invading pathogens

New test to help physicians identify patients with most lethal forms of triple-negative breast cancer

Researchers find decreased energy metabolism in heart cells as significant independent risk factor

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News